Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.